Tag Archives: Richard L. Wasserman M.D.

Shire expands its portfolio of intravenous and subcutaneous immunoglobulin (IG) products with U.S. FDA approval of CUVITRU

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites Lexington, Mass., 14-Sep-2016 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug … Read the full press release